Posts tagged therapy
BioLight TeaRx to be used in DES trial

BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) announced that one of its subsidiaries, DiagnosTear, has signed a services agreement with a pharmaceuticals company to provide analysis services with its TeaRx multi-parameter diagnostic assays for use in an clinical trial for dry eye syndrome (DES).

Read More
HCW starts Cidara Therapeutics at buy

H.C. Wainwright launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $25 price target. The stock closed at $10.80 on Dec. 16.

Read More
Galectin completes enrollment in Phase 2b trial ahead of schedule

Galectin Therapeutics (NASDAQ:GALT) has completed enrollment one month early in its NASH-CX Phase 2b trial with 162 subjects with nonalcoholic steatohepatitis (NASH).

The Phase 2b study is testing the company’s GR-MD-02 drug candidate and is being conducted with a primary endpoint of hepatic venous pressure gradient, which the FDA may view as an acceptable surrogate for outcomes for registration trials in this patient population. Top-line results are expected in December 2017.

Read More
Roth starts Kiadis Pharma at buy

Roth Capital Partners has initiated coverage of Kiadis Pharma (Euronext Amsterdam and Brussels: KDS) with a “buy” rating and price target of €17. The stock closed at €11.32 on Wednesday.

“We believe Kiadis Pharma warrants attention from investors because it has zeroed in on an area of high unmet medical need and is planning to take its lead program, ATIR-101, into a well-designed Phase 3 trial later this year,” writes analyst Mark Breidenbach.

Read More
HCW assumes coverage of Vical at buy

H.C. Wainwright analyst Shaunak Deepak assumed coverage of Vical (NASDAQ:VICL) with a “buy” rating and $12 price target. The stock was quoted at $4.39, up 3 cents, Tuesday afternoon.

“With a co-marketable asset in Phase 3 development that is fully funded by partner, Astellas, and a diversified clinical pipeline, we believe Vical should be trading above cash,” Mr. Deepak writes.

Read More
Stifel starts Voyager Therapeutics at buy

Stifel Research launched coverage of Voyager Therapeutics (NASDAQ:VYGR) with a “buy” rating and 12-month price target of $33. The stock closed at $11.81 on Thursday.

Voyager is a clinical stage-gene therapy company with the potential to be the market leader in design, development and commercialization of gene products focused on diseases of the central nervous system (CNS), writes analyst Katherine Breedis.

Read More
Roth starts Heat Biologics at buy

Roth Capital Partners has initiated coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $2.75 price target. The stock closed at 60 cents on Friday.

“Heat Biologics possesses a portfolio of unique, differentiated vaccines that, in our opinion, could bring a much needed boost to the cancer vaccine space, which has been plagued by recent failures,” writes analyst Joseph Pantginis.

Read More
BioLight expands portfolio with eye drops for DES

BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications.

The product was in-licensed from Fischer Pharmaceuticals and RAMOT, the technology transfer arm of the Tel Aviv University.

Read More
Roth ups Celator Pharma price target to $26

Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday

“This is an important next step for Vyxeos on the path to what we believe is likely approval,” writes analyst Joseph Pantginis.

Read More